EE03352B1 - Asendatud kinoksaliin-2,3-diooni derivaatide aminohappe derivaadid kui glutamaatretseptori antagonistid - Google Patents
Asendatud kinoksaliin-2,3-diooni derivaatide aminohappe derivaadid kui glutamaatretseptori antagonistidInfo
- Publication number
- EE03352B1 EE03352B1 EE9700337A EE9700337A EE03352B1 EE 03352 B1 EE03352 B1 EE 03352B1 EE 9700337 A EE9700337 A EE 9700337A EE 9700337 A EE9700337 A EE 9700337A EE 03352 B1 EE03352 B1 EE 03352B1
- Authority
- EE
- Estonia
- Prior art keywords
- derivatives
- substituted quinoxaline
- amino acid
- receptor antagonists
- glutamate receptor
- Prior art date
Links
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical class C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003862 amino acid derivatives Chemical class 0.000 title 1
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002660 Anoxia Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010014498 Embolic stroke Diseases 0.000 abstract 1
- 229940122459 Glutamate antagonist Drugs 0.000 abstract 1
- 208000010496 Heart Arrest Diseases 0.000 abstract 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028923 Neonatal asphyxia Diseases 0.000 abstract 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 abstract 1
- 208000001286 intracranial vasospasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000004090 neuroprotective agent Substances 0.000 abstract 1
- 208000033300 perinatal asphyxia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005809 status epilepticus Diseases 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/474,878 US5614508A (en) | 1995-06-07 | 1995-06-07 | Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists |
| PCT/US1996/006816 WO1996040649A1 (en) | 1995-06-07 | 1996-05-13 | Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE03352B1 true EE03352B1 (et) | 2001-02-15 |
Family
ID=23885313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EE9700337A EE03352B1 (et) | 1995-06-07 | 1996-05-13 | Asendatud kinoksaliin-2,3-diooni derivaatide aminohappe derivaadid kui glutamaatretseptori antagonistid |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5614508A (xx) |
| EP (1) | EP0832074B1 (xx) |
| JP (1) | JPH11509176A (xx) |
| KR (1) | KR19990022483A (xx) |
| CN (1) | CN1125818C (xx) |
| AT (1) | ATE223388T1 (xx) |
| AU (1) | AU714332B2 (xx) |
| BG (1) | BG63306B1 (xx) |
| CA (1) | CA2219417A1 (xx) |
| CZ (1) | CZ290418B6 (xx) |
| DE (1) | DE69623471T2 (xx) |
| DK (1) | DK0832074T3 (xx) |
| EA (1) | EA000605B1 (xx) |
| EE (1) | EE03352B1 (xx) |
| ES (1) | ES2180771T3 (xx) |
| GE (1) | GEP19991869B (xx) |
| MX (1) | MX9708432A (xx) |
| NO (1) | NO309473B1 (xx) |
| NZ (1) | NZ308316A (xx) |
| PL (1) | PL323738A1 (xx) |
| PT (1) | PT832074E (xx) |
| SK (1) | SK283637B6 (xx) |
| UA (1) | UA54396C2 (xx) |
| WO (1) | WO1996040649A1 (xx) |
| ZA (1) | ZA964787B (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9419318D0 (en) * | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
| WO1997046539A1 (en) * | 1996-06-05 | 1997-12-11 | Warner-Lambert Company | Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| AU3571997A (en) * | 1996-08-01 | 1998-02-25 | Warner-Lambert Company | Novel glutamate receptor antagonists: fused cycloalkyl quinoxalinediones |
| US6015800A (en) * | 1997-09-03 | 2000-01-18 | Warner-Lambert Company | Substituted quinoxaline-2-ones as glutamate receptor antagonists |
| IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| GB9908175D0 (en) * | 1999-04-09 | 1999-06-02 | Lilly Co Eli | Method of treating neurological disorders |
| US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| CN103435561B (zh) * | 2013-08-19 | 2016-08-10 | 上海交通大学 | 一种新型d-氨基酸氧化酶抑制剂及其制备和应用 |
| CN103664806B (zh) * | 2013-12-16 | 2016-06-29 | 山东汇海医药化工有限公司 | 一种n-乙酰乙酰基-6-甲氧基-7-氨基喹喔啉-2，3-二酮的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2271187A (en) * | 1939-09-12 | 1942-01-27 | Aluminum Co Of America | Sheet handling apparatus |
| US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
| US4206216A (en) * | 1976-02-13 | 1980-06-03 | Merck & Co., Inc. | Antihypertensive N-heterocyclicalanines |
| EP0484437A4 (en) * | 1989-07-27 | 1994-06-01 | Searle & Co | Renal-selective prodrugs for the treatment of hypertension |
| EP0488959A3 (en) * | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
| JPH05117276A (ja) * | 1991-10-23 | 1993-05-14 | Sumitomo Pharmaceut Co Ltd | 新規な３環性キノキサリンジオン誘導体 |
| JPH06228112A (ja) * | 1993-02-05 | 1994-08-16 | Yamanouchi Pharmaceut Co Ltd | （１ｈ，４ｈ）キノキサリン誘導体 |
| TW260660B (xx) * | 1993-04-22 | 1995-10-21 | Sumitomo Pharma | |
| WO1994026747A1 (en) * | 1993-05-13 | 1994-11-24 | Neurosearch A/S | Ampa antagonists and a method of treatment therewith |
| US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
-
1995
- 1995-06-07 US US08/474,878 patent/US5614508A/en not_active Expired - Fee Related
-
1996
- 1996-05-13 SK SK1589-97A patent/SK283637B6/sk unknown
- 1996-05-13 CA CA002219417A patent/CA2219417A1/en not_active Abandoned
- 1996-05-13 AU AU57918/96A patent/AU714332B2/en not_active Ceased
- 1996-05-13 EE EE9700337A patent/EE03352B1/xx not_active IP Right Cessation
- 1996-05-13 DE DE69623471T patent/DE69623471T2/de not_active Expired - Fee Related
- 1996-05-13 JP JP9500556A patent/JPH11509176A/ja active Pending
- 1996-05-13 PL PL96323738A patent/PL323738A1/xx unknown
- 1996-05-13 ES ES96914615T patent/ES2180771T3/es not_active Expired - Lifetime
- 1996-05-13 AT AT96914615T patent/ATE223388T1/de not_active IP Right Cessation
- 1996-05-13 EP EP96914615A patent/EP0832074B1/en not_active Expired - Lifetime
- 1996-05-13 CN CN96194485A patent/CN1125818C/zh not_active Expired - Fee Related
- 1996-05-13 WO PCT/US1996/006816 patent/WO1996040649A1/en not_active Application Discontinuation
- 1996-05-13 MX MX9708432A patent/MX9708432A/es not_active IP Right Cessation
- 1996-05-13 PT PT96914615T patent/PT832074E/pt unknown
- 1996-05-13 EA EA199800006A patent/EA000605B1/ru not_active IP Right Cessation
- 1996-05-13 KR KR1019970708964A patent/KR19990022483A/ko not_active Application Discontinuation
- 1996-05-13 GE GEAP19964089A patent/GEP19991869B/en unknown
- 1996-05-13 CZ CZ19973710A patent/CZ290418B6/cs not_active IP Right Cessation
- 1996-05-13 UA UA98010045A patent/UA54396C2/uk unknown
- 1996-05-13 NZ NZ308316A patent/NZ308316A/en unknown
- 1996-05-13 DK DK96914615T patent/DK0832074T3/da active
- 1996-06-06 ZA ZA964787A patent/ZA964787B/xx unknown
-
1997
- 1997-11-27 BG BG102080A patent/BG63306B1/bg unknown
- 1997-12-05 NO NO975701A patent/NO309473B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO309473B1 (no) | 2001-02-05 |
| DE69623471T2 (de) | 2003-08-07 |
| NO975701L (no) | 1998-01-30 |
| PT832074E (pt) | 2003-01-31 |
| EP0832074A1 (en) | 1998-04-01 |
| AU714332B2 (en) | 1999-12-23 |
| CN1125818C (zh) | 2003-10-29 |
| NZ308316A (en) | 2001-04-27 |
| UA54396C2 (uk) | 2003-03-17 |
| ES2180771T3 (es) | 2003-02-16 |
| CZ290418B6 (cs) | 2002-07-17 |
| SK158997A3 (en) | 1998-05-06 |
| SK283637B6 (sk) | 2003-11-04 |
| WO1996040649A1 (en) | 1996-12-19 |
| MX9708432A (es) | 1998-02-28 |
| ATE223388T1 (de) | 2002-09-15 |
| CA2219417A1 (en) | 1996-12-19 |
| PL323738A1 (en) | 1998-04-14 |
| GEP19991869B (en) | 1999-12-06 |
| KR19990022483A (ko) | 1999-03-25 |
| JPH11509176A (ja) | 1999-08-17 |
| AU5791896A (en) | 1996-12-30 |
| BG102080A (en) | 1998-11-30 |
| CN1187190A (zh) | 1998-07-08 |
| EA000605B1 (ru) | 1999-12-29 |
| NO975701D0 (no) | 1997-12-05 |
| DK0832074T3 (da) | 2002-12-16 |
| CZ371097A3 (cs) | 1998-05-13 |
| EA199800006A1 (ru) | 1998-08-27 |
| DE69623471D1 (de) | 2002-10-10 |
| EP0832074B1 (en) | 2002-09-04 |
| US5614508A (en) | 1997-03-25 |
| ZA964787B (en) | 1997-01-08 |
| BG63306B1 (bg) | 2001-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE03352B1 (et) | Asendatud kinoksaliin-2,3-diooni derivaatide aminohappe derivaadid kui glutamaatretseptori antagonistid | |
| RU94046067A (ru) | Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты, фармкомпозиция и способ лечения | |
| EE03683B1 (et) | Asendatud kinoksaliin-2,3-dioonide alküülamiinderivaadid kui glutamaatretseptori antagonistid | |
| MX9708563A (es) | Derivados aminociclicos de quinoxalina 2, 3-diones substituidos como antagonistas del receptor de glutamato. | |
| FI960051A (fi) | Difluoristatonianalogeja | |
| CO5310533A1 (es) | Derivados de amida de 2,3-dionas de quinoxalina como antago- nistas de receptor de glutamato | |
| MXPA04003215A (es) | Derivados de triazapina como agentes neurotroficos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20050513 |